BioSupply Trends Quarterly logo
Search
Close this search box.
Summer 2020 - Vaccines

Large-Dose Albumin Supplementation Does Not Reduce Mortality or Need for Critical Care Interventions: Retrospective Review

Serious burns affecting ≥20% of the total body surface area (TBSA) trigger capillary leakage and loss of serum proteins, including albumin, commonly resulting in persistent hypoalbuminemia. Investigators conducted a retrospective review of 38 cases treated at Taipei Veterans General Hospital between January 2007 and December 2018 to determine whether more aggressive albumin supplementation can benefit major burn patients with persistent hypoalbuminemia.

No significant differences were identified in baseline characteristics of patients who received <25 mg/kg/%TBSA/day of human albumin solutions and those who received more than this quantity. Renal replacement therapy, duration of mechanical ventilation, length of stay in the burn unit and in-hospital mortality were not statistically different between the two groups. The serum C-reactive protein/ albumin ratio was associated with in-hospital mortality (P = 0.036). The investigators concluded no significant mortality benefit was associated with administration of large quantities of supplemental albumin to correct prolonged hypoalbuminemia in major burn patients.

References

Chen YF, Ma H, Perng CK, et al. Albumin supplementation may have limited effects on prolonged hypoalbuminemia in major burn patients: An outcome and prognostic factor analysis. J Chin Med Assoc 2020 Feb;83(2):206-10.

BSTQ Staff
BioSupply Trends Quarterly [BSTQ] is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace. With timely and critical information, each themed issue covers topics ranging from product breakthroughs, industry insights and innovations, up-to-the-minute news on the latest clinical trials, accessibility, and service and safety concerns.